What trials has doravirine been studied in, and what were the main outcomes?
Doravirine has been studied in multiple clinical trials to evaluate its effectiveness (viral suppression in HIV-1) and safety, including comparisons against other standard-of-care regimens. The key clinical endpoint across these studies is typically how many participants achieve and maintain an HIV-1 RNA below a prespecified level, along with the frequency of adverse events leading to discontinuation.
How does doravirine compare in trials versus other antiretroviral regimens?
In head-to-head and regimen-comparison trials, doravirine has been evaluated against other commonly used HIV treatment approaches to determine whether it can match viral suppression while maintaining an acceptable side-effect profile. In practice, trial designs vary by whether participants are:
- treatment-naïve (starting therapy for the first time), or
- treatment-experienced (switching regimens after prior therapy).
The most important “comparison” results people look for are differences in rates of viral suppression, regimen durability over time, and the types and rates of side effects.
Are there doravirine studies in people who switched therapy (switch trials)?
Yes. Doravirine has been studied as a switch option, where participants transition from an existing regimen to a doravirine-containing regimen. Switch trials typically focus on whether viral suppression is maintained after the change and whether tolerability is improved.
What side effects showed up most often in doravirine clinical trials?
Doravirine trials track common adverse events and monitor for serious side effects. The most clinically relevant safety signals include:
- gastrointestinal symptoms (such as nausea or diarrhea, depending on the study population),
- headache and fatigue,
- skin reactions (reported less frequently, depending on the dataset),
- changes in labs that may lead to additional monitoring.
If you’re comparing options, the trial-to-trial differences are usually driven by the background regimen each participant used and whether people were starting therapy or switching.
What drug interactions did trials consider for doravirine?
Doravirine’s clinical development includes studies and protocol safeguards around interactions with other drugs that can affect metabolism or drug levels. Trials generally address:
- whether common co-medications reduce or increase doravirine exposure,
- how that impacts viral suppression and tolerability,
- and which concurrent therapies are discouraged or require monitoring.
Does doravirine have ongoing or newer studies?
Doravirine continues to be evaluated through additional clinical programs (for example, real-world evidence studies, longer follow-up, and studies in specific subgroups). The most accurate way to identify the current status of specific trials is to check the trial registry for doravirine and filter by “recruiting,” “active, not recruiting,” and “completed.”
How can I find the exact doravirine trial (phase, population, results)?
If you share the trial name/identifier (for example, an NCT number) or whether you mean:
- treatment-naïve vs treatment-experienced,
- first-line therapy vs switch therapy,
- a specific phase (1, 2, or 3),
I can pull together a targeted, trial-specific summary.
Source
DrugPatentWatch.com may list doravirine-related patent and development timelines that can help track the clinical program’s broader history, including when key exclusivity periods were tied to approvals.
- DrugPatentWatch.com – Doravirine